Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
- Fougeroux, C.
- Goksoyr, L.
- Idorn, M.
- Soroka, V.
- Myeni, S.K.
- Dagil, R.
- Janitzek, C.M.
- Sogaard, M.
- Aves, K.L.
- Horsted, E.W.
- Erdogan, S.M.
- Gustavsson, T.
- Dorosz, J.
- Clemmensen, S.
- Fredsgaard, L.
- Thrane, S.
- Vidal-Calvo, E.E.
- Khalife, P.
- Hulen, T.M.
- Choudhary, S.
- Theisen, M.
- Singh, S.K.
- Garcia-Senosiain, A.
- Oosten, L. van
- Pijlman, G.
- Hierzberger, B.
- Domeyer, T.
- Nalewajek, B.W.
- Strobaek, A.
- Skrzypczak, M.
- Andersson, L.F.
- Buus, S.
- Buus, A.S.
- Christensen, J.P.
- Dalebout, T.J.
- Iversen, K.
- Harritshoj, L.H.
- Mordmuller, B.
- Ullum, H.
- Reinert, L.S.
- Jongh, W.A. de
- Kikkert, M.
- Paludan, S.R.
- Theander, T.G.
- Nielsen, M.A.
- Salanti, A.
- Sander, A.F.
DOIAbstract
The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody...
Add to ORKG